Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Cardiology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Cardiology Other
    The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials - (BMJ)
    FDA Approves Dronedarone for Atrial Fibrillation or Atrial Flutter - (DGNews)
    Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease - (JAMA)
    Novel and conventional biomarkers for prediction of incident cardiovascular events in the community - (JAMA)
    Kidney function and risk of cardiovascular disease and mortality in women: a prospective cohort study - (BMJ)

    News archive

     Recent webcasts/CME - Cardiology Other
    • State of the Science in Managing the Treatment-Experienced Patient With HIV
    • What's New in Managing Treatment-Experienced Patients With HIV?
    • Applying Data to Practice: Case Vignettes
    • Rheumatoid Arthritis: The Heart of the Matter Assessing Cardiovascular Risk in Patients with Rheumatoid Arthritis
      Supraventricular Tachycardia in Children and Adolescents

      Webcasts/CME archive

       Recent cases - Cardiology Other
        Cardiogenic Shock Caused by Disulfiram
        Congenital Atresia of the Left Main Coronary Artery Associated With Patent Ductus Arteriosus and Aortic Regurgitation
        Pleural Effusion and Pulmonary Hypertension in a Patient With Parkinson Disease Treated With Cabergoline
        A Well-Circumscribed Density Along the Right Heart Border
        A Case of Massive Pulmonary Embolism with ST Elevation in Leads V1-4

        Cases archive
          




        my personal edition > cardiology other > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Knowledge About Beta-Blocker Side Effects May Lead To Erectile Dysfunction

        A DGReview of :"Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo"
        European Heart Journal

        11/18/2003
        By Jill Taylor


        Erectile dysfunction (ED) in patients taking beta-blockers may be mostly psychological, appearing more frequently in patients who know of this side effect, and is reversed in most cases by placebo, say researchers.

        The complaint of ED is common in cardiovascular disease patients treated with beta-blockers. However, evidence suggests a higher rate of sexual dysfunction occurs in untreated men with cardiovascular disease compared with men of similar age, leaving the actual cause of ED unclear.

        To assess whether the effect of beta-blockers on ED is related to patient knowledge of side effects, Antonello Silvestri, MD, of the Department of Medical Sciences, San Raffaele-Rome, Tosinvest Sanita, Rome, Italy, and colleagues performed a 2-phase, single cross-over study in 96 men (mean age: 52±7 years) with newly diagnosed cardiovascular disease without ED.

        Forty percent of patients had hypertension and 60% had angina. The International Index of Erectile Function questionnaire was administered at study baseline, at the end of phase 1, and at the end of each treatment period of phase 2.

        In the first study phase, patients received Atenolol 50 mg over 90 days. Divided into 3 groups of 32 patients, group A was blinded on the drug given, group B was informed on the drug but not side effects, and group C was informed on the drug and potential side effects.

        ED incidence after 3 months was 3.1% in group A, 15.6% in group B, and 31.2% in group C (P < .01).

        Patients reporting ED entered study phase 2 and were randomised to receive Sildenafil citrate 50mg or placebo. Both treatments were equally effective in reversing erectile dysfunction.

        "In conclusion the occurrence of erectile dysfunction on beta-blockers is low, much lower than commonly thought," say the researchers. "The results of the present study suggest that both patient's and doctor's expectations on the risk of experiencing erectile dysfunction may influence the occurrence of this bothersome side-effect."

        Eur Heart J 2003 Nov;24:21:1928-32. "Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send